Merck KGaA, Darmstadt, Germany, Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare ...
Zacks Investment Research on MSN
Merck's anti-TL1A antibody meets goal in ulcerative colitis study
Merck MRK announced positive results from Study 2 of the late-stage ATLAS-UC study, which evaluated tulisokibart, its ...
Merck remains in focus after important pipeline developments, new product approvals, and clinical progress strengthen ...
Merck & Co Inc. MRK on Monday said its investigational therapy tulisokibart achieved the primary endpoint in a Phase 3 study ...
Merck remains in focus as combination therapy development and pipeline progress shape the broader healthcare landscape.
Merck & Co. will partner with Protillion Biosciences to discover multiple new therapy candidates, through a collaboration ...
The second edition of this very valuable resource has all the attributes of the first. Written for the layperson, articles are clear, comprehensive and detailed. There are excellent charts and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results